Keywords advanced colorectal cancer DR5 CDK4 antibody-drug conjugate Oba01 abemaciclib synergetic effect Introduction Colorectal cancer (CRC) is the third most common causes of cancer-related death and the second in terms of mortality, accounting for 10% of all cancer cases and related death.1,2 Among 20% of newly diagnosed patients with metastatic CRC, less than 20% survive for more than 5 years,3,4 making it a major public health and socioeconomic concern.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ruxia
Contact Ruxia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack